5-FU/leucovorin (5FU/LV) combined with irinotecan (CPT-11) and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.

被引：0
|
作者：
Assaf, E.
Verlinde-Carvalho, M.
Delbaldo, C.
Grenier, J.
Sellam, Z.
Pouessel, D.
Sobhani, I.
Tayar, C.
Piedbois, P.
Culine, S.
机构：
[1] Hop Henri Mondor, F-94010 Creteil, France
[2] Henri Mondors Hosp, Creteil, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e14584
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14584
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FLUOROURACIL/LEUCOVORIN (5FU/LV) COMBINED WITH IRINOTECAN AND OXALIPLATIN (FOLFIRINOX) AS SECOND LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA
    Assaf, E.
    Verlinde-Carvalho, M.
    Delbaldo, C.
    Grenier, J.
    Sellam, Z.
    Pouessel, D.
    Sobhani, I.
    Tayyar, C.
    Paul, M.
    Culine, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 233 - 233
  • [2] 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
    Assaf, Elias
    Verlinde-Carvalho, Muriel
    Delbaldo, Catherine
    Grenier, Julien
    Sellam, Zineb
    Pouessel, Damien
    Bouaita, Linda
    Baumgaertner, Isabelle
    Sobhani, Iradj
    Tayar, Claude
    Paul, Muriel
    Culine, Stephane
    ONCOLOGY, 2011, 80 (5-6) : 301 - 306
  • [3] Modified FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for gemcitabine-resistant or -refractory advanced pancreatic cancer
    Lee, S. C.
    Lee, K.
    Bae, S. B.
    Kim, Han Jo
    Oh, S. Y.
    Song, S. Y.
    Hong, D. S.
    Kim, Hyun Jung
    Yoon, J.
    Lim, D. H.
    Lee, S. I.
    Won, J. H.
    Lee, N.
    Kim, K.
    Lee, H. W.
    Lee, H. R.
    Nam, E. M.
    Jang, J. S.
    Hwang, I. G.
    Kang, J. H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S456 - S456
  • [4] A phase II study with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) in patients with metastatic colorectal cancer
    Destefanis, M
    Dalla Mola, A
    Ostellino, O
    Capello, C
    Milanesi, E
    Grillo, C
    Castiglione, F
    Venturino, A
    Porcile, G
    ANNALS OF ONCOLOGY, 2000, 11 : 67 - 67
  • [5] 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) versus CPT-11 followed by 5-FU/LV at relapse in patients with advanced colorectal carcinoma. Phase III randomized study
    Tsavaris, N.
    Kosmas, C.
    Skopelitis, E.
    Papadoniou, N.
    Polyzos, A.
    Zografos, G.
    Diamartis, N.
    Ntokou, A.
    Tsaousi, S.
    Sarantonis, I
    Adoniou, E.
    Gryniatsos, J.
    Felekouras, E.
    Papalambros, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 81 - 81
  • [6] A randomized phase III trial of adjuvant radio - Chemotherapy comparing irinotecan (CPT-11), 5FU and leucovorin to 5FU and leucovorin in patients with rectal cancer
    Kalofonos, Haralabos P.
    Pentheroudakis, George
    Rigatos, Sotirios
    Papakostas, Pavlos
    Tsavdaridis, Dimitrios
    Xiros, Nikolaos
    Dimopoulos, Meletios A.
    Galani, Eleni
    Pectasides, Dimitrios
    Fountzilas, George
    ANNALS OF ONCOLOGY, 2006, 17 : 116 - 116
  • [7] Weekly irinotecan (CPT-11) as second-line treatment in patients with 5-FU refractory metastatic colorectal cancer.
    Beni, A
    Zidan, J
    Epelbaum, R
    Sikorsky, N
    Michaeli, B
    Skigin, R
    Kuten, A
    ANNALS OF ONCOLOGY, 2000, 11 : 55 - 55
  • [8] Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma - A phase III randomized study
    Tsavaris, Nicolas
    Kosmas, Christos
    Skopelitis, Helias
    Papadoniou, Nicitas
    Polyzos, Aristidis
    Zografos, George
    Adoniou, Efstathios
    Gryniatsos, John
    Felekouras, Evangelos
    Zacharakis, Michalis
    Sigala, Francheska
    Bacoyiannis, Christos
    Papastratis, George
    Papalambros, Efstathios
    CHEMOTHERAPY, 2007, 53 (04) : 282 - 291
  • [9] Cisplatin /5-FU (DDP/FU) as 2nd-line chemotherapy after CPT-11 (Irinotecan) failure for patients with metastatic gastric adenocarcinoma
    Thuss-Patience, PC
    Kretzschmar, A
    Tilgner, J
    Charles, A
    Dörken, B
    Reichardt, P
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S149 - S150
  • [10] Pilot trial of 5-FU/oxaliplatin (CIFOX) for patients with metastatic colorectal cancer who progressed on 5-FU/LV/CPT-11 (IFL).
    Aparicio, A
    Iqbal, S
    Yang, D
    Groshen, S
    Park, D
    Garcia, A
    Lenz, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 312S - 312S
12345